SCHEMBL6433406

SCHEMBL6433406

COC(=O)c1ccc(C(C)n2c(=O)[nH]c3ccc(C(=O)NCc4ccc(OC)cc4)cc3c2=O)cc1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
MAPT P10636 4/20 0.49
ALDH1A1 P00352 2/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TP53 P04637 2/20 0.46
BACE1 P56817 1/20 0.46
USP2 O75604 1/20 0.45
MMP13 P45452 2/20 0.44
B3GNT2 Q9NY97 1/20 0.44
ESR1 P03372 1/20 0.43
KDM4E B2RXH2 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
PDE4A P27815 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6236712 0.94 MEN1 (0.52) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL6727454 0.94 MEN1 (0.50) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL6233925 0.93 MEN1 (0.51) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL6234330 0.92 MEN1 (0.49) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL6218995 0.91 MEN1 (0.54) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL6237879 0.90 DRD2 (0.46) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL6235396 0.89 MEN1 (0.52) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL6231875 0.88 MEN1 (0.51) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL6232533 0.88 MEN1 (0.53) MEN1KMT2AMAPTALDH1A1NPC1
SCHEMBL6238482 0.88 MEN1 (0.51) MEN1KMT2AMAPTALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1368324-A1 QUINAZOLINES AS MMP-13 INHIBITORS Warner-Lambert Company LLC (US) 2003-12-10 EP claimed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US claimed
WO-2002064572-A1 QUINAZOLINES AS MMP-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO claimed
EP-1536786-A1 COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB WARNER-LAMBERT COMPANY LLC (US) 2005-06-08 EP disclosed
WO-2004006913-A1 COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB WARNER-LAMBERT COMPANY LLC (US) 2004-01-22 WO disclosed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193377-A1 Quinazolines as MMP-13 inhibitors MMP13, MMP9, MMP3 MEN1 4715/4885KMT2A 3258/4885MAPT 4823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.